Authors’ reply to Mangin and colleagues
BMJ 2011; 343 doi: https://doi.org/10.1136/bmj.d5079 (Published 10 August 2011) Cite this as: BMJ 2011;343:d5079
- Shaughn O’Brien, professor of academic obstetrics and gynaecology1,
- Andrea Rapkin, professor of obstetrics and gynaecology2,
- Lorraine Dennerstein, professorial fellow3,
- Tracy Nevatte, postdoctoral research associate4
- 1Keele University and University Hospital of North Staffordshire, Staffordshire, UK
- 2David Geffen School of Medicine at UCLA, Department of Obstetrics and Gynecology, Box 951740, Los Angeles, CA, USA
- 3National Aging Research Institute, Department of Psychiatry, University of Melbourne, Vic, Australia
- 4Keele University, Institute of Science and Technology in Medicine, Guy-Hilton Research Centre, Stoke on Trent, Staffordshire ST4 7QB, UK
- t.nevatte{at}pmed.keele.ac.uk
It has been called to our attention that our statement that selective serotonin reuptake inhibitors (SSRIs) have not been shown to be teratogenic is in error.1
Selective serotonin reuptake inhibitors cross the placenta and are found in breast milk.2 Although the risk of major malformations is very low, the severity of the potential structural and behavioural risks for the infant associated with taking SSRIs and selective noradrenaline reuptake inhibitors (SNRIs) in the first trimester of pregnancy is real and must be weighed against the risks associated with severe depression and anxiety in pregnancy. …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.